Ubs Group Ag Cyclo Therapeutics, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 4,828 shares of CYTH stock, worth $5,890. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,828

Holding current value

$5,890

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$1.39 - $1.9 $6,710 - $9,173	4,828 New	4,828 $6,000
Q3 2023 Nov 09, 2023	BUY	$1.26 - $1.88 $110 - $165	88 New	88 $0
Q1 2023 May 12, 2023	SELL	$0.82 - $2.27 $959 - $2,655	-1,170 Reduced 41.64%	1,640 $1,000
Q4 2022 Feb 08, 2023	BUY	$0.95 - $1.99 $2,669 - $5,591	2,810 New	2,810 $3,000
Q2 2022 Aug 10, 2022	SELL	$1.97 - $3.21 $2,951 - $4,808	-1,498 Reduced 65.39%	793 $2,000

Q1 2022 May 16, 2022	SELL	$2.62 - $4.51 $27,824 - $47,896	-10,620 Reduced 82.26%	2,291 $7,000
Q4 2021 Feb 14, 2022	SELL	$3.47 - $7.34 $93,700 - $198,202	-27,003 Reduced 67.65%	12,911 $48,000
Q3 2021 Nov 15, 2021	BUY	$6.21 - $10.04 $178,972 - $289,352	28,820 Added 259.78%	39,914 $269,000
Q2 2021 Aug 13, 2021	BUY	$6.58 - $10.85 $68,405 - $112,796	10,396 Added 1489.4%	11,094 $113,000
Q1 2021 May 12, 2021	BUY	$4.25 - $13.33 $2,966 - $9,304	698 New	698 $6,000

Others Institutions Holding CYTH

# of Institutions

Shares Held

2.16M

Call Options Held

Put Options Held

Epiq Capital Group, LLC San Francisco, CA

854K
Shares

$1.04 Million
0.47% of portfolio
Founders Fund V Management, LLC San Francisco, CA

481K
Shares

$586,463
3.08% of portfolio
Vanguard Group Inc Valley Forge, PA

397K
Shares

$483,922
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

160K
Shares

$194,893
0.0% of portfolio
Founders Fund Vi Management, LLC San Francisco, CA

110K
Shares

$134,228
57.89% of portfolio

View Full List

About Cyclo Therapeutics, Inc.

Ticker CYTH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 8,439,440
Market Cap $10.3M
Description
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...

More about CYTH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account